|
|
|
 |
FDA Approval Activities for this Drug…
Sonata (zaleplon) CIV Capsules, Wyeth-Ayerst NDA 20-859/S2 & S3 5/31/02 6/3/02 Sonata (zaleplon) Capsule, 5 mg & 10 mg, Wyeth-Ayerst NDA 20-859/S1 2/22/01 3/5/01 3/5/01 Sonata (zaleplon) Capsule, Wyeth-Ayerst NDA 20-859 8/13/99 3/21/00 3/21/00 7/3/00 Sonata Indications: short-term treatment of insomnia ZALEPLON Capsule; 10MG SONATA JONES 020859 ZALEPLON Capsule; 5MG SONATA JONES | Zaleplon Capsules, Roxane Labs, Tentative Approval | Zaleplon Capsules, Teva Pharma, Tentative Approval | Zaleplon Capsules, Genpharm, Tentative Approval | Sonata (zaleplon) Capsules, King Pharma, Labeling Revision | Zaleplon Capsules, Roxane Laboratories, Inc., Approval | Zaleplon Capsules, Genpharm ULC, Approval | Zaleplon Capsules, Sandoz, Inc., Approval | Zaleplon Capsules, Upsher-Smith Laboratories, Inc., Approval | Zaleplon Capsules, Aurobindo Pharma USA, Inc., Approval | Zaleplon Capsules, Unichem Pharmaceuticals USA, Inc., Approval | Zaleplon Capsules, Teva Pharmaceuticals USA, Approval | Zaleplon Capsules, Cipla, Ltd., Approval | Zaleplon Capsules, West-ward Pharmaceutical Corp., Approval | Zaleplon Capsules, Orchid Healthcare, Approval
  
|